Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Completed · Phase 1/Phase 2
Conditions studied: Head and Neck Neoplasms
In brief
The objective of this study is to evaluate in a 3 +3 design, the safety of escalating doses of Monalizumab given IV in combination with cetuximab in patients who have received prior systemic regimen(s) for recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). Cohorts expansion will evaluate antitumor activity of monalizumab and cetuximab with or without anti-PD(L)1
Key facts
- Study ID
- NCT02643550
- Run by
- Innate Pharma
- People needed
- 143
- Starts
- 2015-12-01
- Expected to finish
- 2023-03-28
- Last updated by the study team
- 2023-05-12
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of California, Moores Cancer Center — La Jolla, California, United States
- Stanford Cancer Center — Stanford, California, United States
- University of Chicago — Chicago, Illinois, United States
- University of Maryland, Greenebaum Comprehensive Cancer Center — Baltimore, Maryland, United States
- Washington University School of Medicine — St Louis, Missouri, United States
- Icahn School of Medicine at Mount Sinaï — New York, New York, United States
- University of Pennsylvania — Philadelphia, Pennsylvania, United States
- Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States
- Vanderbilt University Medical Center — Nashville, Tennessee, United States
- Centre Jean Perrin — Clermont-Ferrand, France
- Centre Oscar Lambret — Lille, France
- Centre Leon Berard — Lyon, France
- Hopital La Timone — Marseille, France
- Institut Regional du Cancer de Montpellier — Montpellier, France
- Centre Antoine Lacassagne — Nice, France
- Centre Eugene Marquis — Rennes, France
- ICO Rene Gauducheau — Saint-Herblain, France
- Institut Gustave Roussy — Villejuif, France
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.